Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Leuk Lymphoma
Päätekijät: DiMaggio, Elizabeth, Zhou, Jun-Min, Caddell, Ryan, Tombleson, Rebecca, Perkins, Janelle, Anasetti, Claudio, Khimani, Farhad, Pidala, Joseph, Nishihori, Taiga, Perez, Lia, Betts, Brian, Fernandez, Hugo F., Mishra, Asmita
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771324/
https://ncbi.nlm.nih.gov/pubmed/32133897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1731498
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia